Document Type

Conference Proceeding

Publication Date


Publication Title

J Am Acad Dermatol


Background: Tapinarof cream 1% QD was efficacious and well tolerated versus vehicle in adults with mild-to-severe plaque psoriasis in 2 double-blind 12-week Phase 3 trials (PSOARING 1&2). We report secondary efficacy from PSOARING 3, the LTE trial assessing tapinarof during intermittent treatment based on Physician Global Assessment (PGA) score.

Methods: Eligible PSOARING 1&2 completers could enroll for 40-weeks’ open-label tapinarof 1% QD and 4-weeks’ follow-up in PSOARING 3. Patients entering with PGA ≥1 were treated until PGA = 0. Patients entering with/achieving PGA = 0 discontinued tapinarof until PGA ≥2, then retreated until PGA = 0.

Results: 91.6% (n = 763) eligible patients enrolled in PSOARING 3. Efficacy improved beyond 12-week pivotal trials and was maintained over time. In PSOARING 1&2, overall mean baseline body surface area (BSA) affected was 7.6–7.9% and Psoriasis Area Severity Index (PASI) was 8.87–9.12. PSOARING 3 baseline mean BSA affected was 4.7% (3.3% and 7.3% previously treated with tapinarof and vehicle, respectively) and mean PASI was 4.76 (3.28 and 7.69 tapinarof and vehicle, respectively). At week 40, significant improvements beyond pivotal trials were observed: overall mean improvement from baseline in BSA affected was –2.0%; PASI75 and PASI90 responses were 29.4% and 17.5%, respectively (beyond the PASI75 of 36.1% and 47.6%; PASI90 of 18.8% and 20.9% in PSOARING 1&2, respectively). No new safety signals were observed.

Conclusion: Continued improvements beyond 12 weeks and durable responses/no tachyphylaxis were observed across secondary efficacy outcomes which, together with previously reported high rates of complete disease clearance (PGA = 0) and ∼4-month remittive effect off-therapy, differentiate tapinarof from other topical therapies.





First Page




To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.